Showing results (51-60 of 123) with videos related to

Sort By:
Pageof 13
The Journal of Antimicrobial Chemotherapy|January 20, 2023
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055Antoine Bachelard, Valentina Isernia, Charlotte Charpentier, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2019
Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR studyMarc-Antoine Valantin, Lise Durand, Marc Wirden, et al.
Sexually Transmitted Infections|October 24, 2025
Willingness to participate in a long-acting injectable cabotegravir HIV pre-exposure prophylaxis study among men who have sex with men in the French ANRS-PREVENIR cohortAugust Eubanks, Maxime Hoyer, Abdourahmane Sow, et al.
AIDS (London, England)|November 17, 2023
Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with tenofovir disoproxil/emtricitabineSylvain Chawki, Lauriane Goldwirt, Mayssam El Mouhebb, et al.
The Journal of Antimicrobial Chemotherapy|September 24, 2015
Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial)Cathia Soulié, Lambert Assoumou, Mélanie Darty, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2016
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial)Laurence Slama, Roland Landman, Lambert Assoumou, et al.
The Journal of Antimicrobial Chemotherapy|August 2, 2020
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular diseaseAna Gonzalez-Cordon, Lambert Assoumou, Miguel Camafort, et al.
The Lancet Regional Health. Europe|August 27, 2024
Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trialJade Ghosn, Lambert Assoumou, Moussa Ouattara, et al.
Open Forum Infectious Diseases|June 22, 2026
Effectiveness and Safety of Lenacapavir-Containing Regimens in Highly Experienced HIV-Infected Patients With Multidrug Resistance: Real-world Results From the French Compassionate Use Program <sup>a</sup>Constance Delaugerre, Sarah Mafi, Arbnor Zenuni, et al.
The Journal of Antimicrobial Chemotherapy|November 4, 2025
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational studyRomain Palich, Jade Ghosn, Karine Lacombe, et al.
Pageof 13